Best of ASCO® Toronto 2024: EMD Serono Lunch Symposium: Exploring the Evolving Landscape of Locally Advanced Squamous Cell Carcinoma of Head & Neck – Practical Considerations – Dr. Sofia Genta and Dr. Jillian Tsai

Best of ASCO® Toronto 2024: EMD Serono Lunch Symposium: Exploring the Evolving Landscape of Locally Advanced Squamous Cell Carcinoma of Head & Neck – Practical Considerations – Dr. Sofia Genta and Dr. Jillian Tsai

Chicago Highlights 2024 Roundtable Discussions
Icon Chair Speaker

Co-Chairs

Dr. Aly-Khan Lalani
Dr. Natasha Leighl

Icon Chair Speaker

Speakers

Dr. Sofia Genta
Dr. Jillian Tsai

Studies/trials discussed:

  • Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data
  • Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study
  • Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care
  • The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients
  • The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients
  • Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma.
  • Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV.
  • Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
  • The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation
  • A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
  • Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): MERIDIAN study.
  • eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT).
  • LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study
  • Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients
  • Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy
  • Precision Radiotherapy: Reduction in Radiation for Oropharyngeal cancer in 30 ROC Trial
  • Hypoxia Directed Treatment of Human Papillomavirus Related Oropharyngeaal Carcinoma.
  • TARGET-HPV: Study Design (NCT03944915)
  • Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Tagged